[
    [
        {
            "time": "2018-06-01",
            "original_text": "Analysts’ Estimates and Recommendations for Eli Lilly in June",
            "features": {
                "keywords": [
                    "Analysts’ Estimates",
                    "Recommendations",
                    "Eli Lilly"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "none"
            },
            "scores": {
                "News_content": "Analysts’ Estimates and Recommendations for Eli Lilly in June",
                "Correlation": 9,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 9,
                "Market_Scope": 5,
                "Time_Proximity": 8,
                "Headline_Structure": 7,
                "Source_Recency": 9
            }
        },
        {
            "time": "2018-06-01",
            "original_text": "Eli Lilly’s Animal Health Business",
            "features": {
                "keywords": [
                    "Eli Lilly",
                    "Animal Health",
                    "Business"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "animal health"
                ],
                "causal_factor": "true",
                "causal_impact": "neutral",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "Eli Lilly’s Animal Health Business",
                "Correlation": 6,
                "Sentiment": 6,
                "Importance": 5,
                "Impact": 5,
                "Duration": 4,
                "Entity_Density": 8,
                "Market_Scope": 4,
                "Time_Proximity": 6,
                "Headline_Structure": 5,
                "Source_Recency": 7
            }
        },
        {
            "time": "2018-06-01",
            "original_text": "Eli Lilly’s Cardiovascular Product Portfolio",
            "features": {
                "keywords": [
                    "Eli Lilly",
                    "Cardiovascular",
                    "Product Portfolio"
                ],
                "sentiment_score": 0.5,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "cardiovascular"
                ],
                "causal_factor": "true",
                "causal_impact": "neutral",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "Eli Lilly’s Cardiovascular Product Portfolio",
                "Correlation": 8,
                "Sentiment": 6,
                "Importance": 7,
                "Impact": 6,
                "Duration": 6,
                "Entity_Density": 8,
                "Market_Scope": 5,
                "Time_Proximity": 6,
                "Headline_Structure": 6,
                "Source_Recency": 7
            }
        },
        {
            "time": "2018-06-01",
            "original_text": "Blog Exposure - Eli Lilly's Taltz(R) Meets Primary Endpoint in Phase-3 Study for Treatment of Ankylosing Spondylitis",
            "features": {
                "keywords": [
                    "Eli Lilly",
                    "Taltz(R)",
                    "Phase-3 Study",
                    "Ankylosing Spondylitis"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "pharmaceuticals",
                    "biotech"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "Blog Exposure - Eli Lilly's Taltz(R) Meets Primary Endpoint in Phase-3 Study for Treatment of Ankylosing Spondylitis",
                "Correlation": 10,
                "Sentiment": 9,
                "Importance": 9,
                "Impact": 8,
                "Duration": 8,
                "Entity_Density": 9,
                "Market_Scope": 6,
                "Time_Proximity": 9,
                "Headline_Structure": 9,
                "Source_Recency": 10
            }
        }
    ]
]